title: [Human bone marrow mesenchymal stem cells have little preventive or therapeutic effect on rat arthritis induced by collagen].
abstract: The aim of this study was to investigate if transfusion of mesenchymal stem cells (MSC) could exhibit beneficial effects on rheumatoid arthritis. Human bone marrow MSC were intraperitoneally injected into Wistar rats with collagen-induced arthritis at a dose of 10(7) on the next day (preventive group) or 2 weeks (treatment group) after collagen II induction, once a week for 2 weeks (preventive group) or 4 weeks (treatment group). The control group was given normal saline (NS) at corresponding time. The symptom scorings were documented weekly from the second week of the induction. On week 6, the hind joints of the rats were pathologically examined and the activation status of splenocytes was analyzed by flow cytometry. The results showed that all the rats developed arthritis and subsequent joint abnormality. On the sixth week, symptom scores of the rats that received MSC preventive (9.5 ± 0.5) or therapeutic (9.4 ± 0.6) infusions had no significant difference between each other, but were significantly greater than those of the NS controls (7.6 ± 0.6, P < 0.05). Consistently, pathological examination on the involved knees showed that the synovitis and arthritis scorings of MSC treated rats were greatly elevated compared with NS controls. Furthermore, the ratios of CD86(+) cells in the spleens of MSC prevention, MSC treatment and NS control groups were (4.16 ± 1.48), (4.06 ± 1.97) and (4.15 ± 2.04) respectively, while those of CD11b/c(+)CD86(+) cells were (1.04 ± 0.68), (0.95 ± 0.56) and (0.98 ± 0.44), all of which were significantly higher than those of healthy controls [(0.97 ± 0.18) and (0.30 ± 0.17), P < 0.05 for both parameters]. It is concluded that MSC infusion has little beneficial effects on collagen-induced arthritis in rats, conversely, MSC therapy aggravated the damage of the involved joints, its underlying mechanisms need to be further investigated.
authors.affiliation: Department of Hematology, General Hospital of Chinese Air Force, Beijing, China.
authors.forename: Yong-Qi
authors.initials: YQ
authors.lastname: Wang
authors.forename: Xiao-Fang
authors.initials: XF
authors.lastname: Cao
authors.forename: Zi-Ming
authors.initials: ZM
authors.lastname: He
authors.forename: Feng-Jun
authors.initials: FJ
authors.lastname: Xiao
authors.forename: Heng-Xiang
authors.initials: HX
authors.lastname: Wang
authors.forename: Zi-Kuan
authors.initials: ZK
authors.lastname: Guo
mesh_terms: D000818:Animals; D001169:Arthritis, Experimental / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D001854:Bone Marrow Cells; D002478:Cells, Cultured; D006801:Humans; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology; D051381:Rats; D017208:Rats, Wistar; D014183:Transplantation, Heterologous; D016896:Treatment Outcome